Trends in mortality and the effects of the COVID-19 pandemic on mortality among adult patients with Staphylococcus aureus bacteremia, 20 US counties, 2005-2022
Clicks: 3
ID: 325840
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
3 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #85 of 207 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 207 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Trends in Staphylococcus aureus bacteremia (SAB) mortality rates in the United States, including the impact of COVID-19, have not been well described. Methods Active, laboratory- and population-based surveillance data from 20 counties (seven states) were used to examine annual, 30-day mortality rates among U.S. adult patients with methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA and MSSA, respectively) bacteremia during 2005-2022. Medical records and state vital statistics data were linked to ascertain death. Multivariable survival analysis estimated the association between recent SARS-CoV-2 infection (a positive SARS-CoV-2 test ≤30 days before incident culture) and mortality among SAB cases, adjusting for demographics and other risk factors. Analyses were stratified by MRSA/MSSA and epidemiologic class (hospital-onset [HO], healthcare-associated community-onset [HACO], and community-associated [CA]). Results Overall, SAB mortality was 21%. Annual SAB mortality rates were generally stable pre-pandemic before increasing by 33% and 41% among HO MRSA and MSSA cases, respectively, and by 49% among CA MRSA cases, but not among HACO or MSSA CA cases, from 2019 through 2021. Among HO cases with recent SARS-CoV-2 infection, annual mortality rates were as high as 75%. Adjusted hazard ratios for recent SARS-CoV-2 infection ranged from 1.9 (95% confidence interval: 1.5-2.3) (HACO MRSA) to 3.0 (95% confidence interval: 2.4-3.7) (HO MSSA). Conclusions Recent SARS-CoV-2 infection was a significant risk factor for death among patients with SAB during 2020-2022. Strengthening infection prevention efforts in similar respiratory pandemics in the future could help prevent increases in SAB mortality rates.
| Reference Key |
openalex_W7203871006
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Carly Adams, Holly M. Biggs, Kelly A. Jackson, Joelle Nadle, Susan Petit, Susan M. Ray, Ruth Lynfield, Carmen Bernu, Ghinwa Dumyati, Marissa Walsh, William Schaffner, H Keipp Talbot, Lee H. Harrison, Isaac See |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag524
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.